Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen

Abstract

Background When emicizumab is dosed according to label, clinicians are obligated to discard or overdose medication due to discrepancies between calculated dose and vial content. The aim of this study was to compose a cost-efficient emicizumab maintenance dosing regimen using Monte Carlo simulation based on vial size, patient-friendly intervals, and patient characteristics, while striving for similar plasma concentrations as observed in clinical trials.

Methods Monte Carlo simulations were used to investigate alternative dosing regimens in patients weighing 3 to 150 kg. Simulated regimens were targeted to achieve median emicizumab plasma concentrations at a steady state (C _av,ss) of 40 to 60 (90% range: 25–95) µg/mL. The cost-efficiency of the alternative dosing regimen was calculated in mg and costs saved per patient per year.

Results The developed alternative dosing regimen achieved similar emicizumab C _av,ss levels compared with the registered dosing regimen with a median deviation of less than 2 µg/mL in 78% of the body-weight categories. A dose of 60 mg every 3 weeks was advised for children weighing 12 to 16 kg, while adults weighing 76 to 85 kg can receive 120 mg emicizumab every week. Compared with the registered weekly dosing of 1.5 mg/kg, alternative dosing saved €35,434 per year in children weighing between 12 and 16 kg. For patients weighing 76 to 85 kg, the median saving was €29,529 (range: €0–€59,057).

Conclusion This alternative maintenance dosing scheme—applicable in patients with hemophilia A receiving emicizumab prophylaxis—reduces financial costs, avoids medication spillage, and is patient-friendly without loss of efficacy.

Keywords

hemophilia A - emicizumab - dose - costs - pharmacokinetics

Author Contributions

L.H.B. and R.A.A.M. performed the analysis and wrote the manuscript. K.Fisher, I.K.-H., and R.E.G.S. proposed the idea of changing the dosing interval proportional to the dose increase. K.Fisher, I.K.-H, A.A.M.D., K. Fijnvandraat, and M.H.C. gave clinical input. K.Fisher, M.H.C., and R.A.A.M. supervised the study. All authors contributed substantially to the critical revision of the manuscript and approved the final draft.

Note

This study was performed as part of the OPTI-CLOT international multicenter research consortium, “Patient tailOred PharmacokineTIc‐guided dosing of CLOTting factor concentrates and desmopressin in bleeding disorders,” which is currently WP6 within the SYMPHONY consortium.

^* Both are last authors.

Publikationsverlauf

Eingereicht: 16. März 2021

Angenommen: 03. Mai 2021

Accepted Manuscript online:
04. Mai 2021

Artikel online veröffentlicht:
25. Juni 2021

• References

• 1 Kitazawa T, Igawa T, Sampei Z. et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18 (10) 1570-1574
• 2 Pipe SW, Shima M, Lehle M. et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6 (06) e295-e305
• 3 Uchida N, Sambe T, Yoneyama K. et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127 (13) 1633-1641
• 4 Mahlangu J, Oldenburg J, Paz-Priel I. et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med 2018; 379 (09) 811-822
• 5 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
• 6 Young G, Liesner R, Chang T. et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134 (24) 2127-2138
• 7 Yoneyama K, Schmitt C, Kotani N. et al. A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet 2018; 57 (09) 1123-1134
• 8 Shima M, Hanabusa H, Taki M. et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv 2017; 1 (22) 1891-1899
• 9 Retout S, Schmitt C, Petry C, Mercier F, Frey N. Population pharmacokinetic analysis and exploratory exposure-bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A. Clin Pharmacokinet 2020; 59 (12) 1611-1625
• 10 Hemlibra. Hemlibra dosing guide. Published 2020. Accessed December 2, 2020 at: https://www.hemlibra-hcp.com/dosing-administration/dosing-calculator.html#calculator
• 11 Groeidiagram TNO. 1–21 jaar Nederlandse Jongens. Published 2010. Accessed December 22, 2020 at: https://www.tno.nl/media/4754/njcx1.pdf
• 12 Groeidiagram TNO. 1–21 jaar Nederlandse meisjes. Published 2010. Accessed December 22, 2020 at: https://www.tno.nl/media/4759/nmcx1.pdf
• 13 Weaving G, Batstone GF, Jones RG. Age and sex variation in serum albumin concentration: an observational study. Ann Clin Biochem 2016; 53 (Pt 1): 106-111
• 14 Roche, Hemlibra. Summary of Product Characteristics. 2018 . Accessed December 22, 2020 at: https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_nl.pdf
• 15 Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 2013; 52 (02) 83-124
• 16 G-standaard. Hemlibra Injvlst 30 mg/1 mL (30 mg/mL) flacon. Accessed December 2, 2020 at: https://kennisbank.knmp.nl/article/G-Standaard_handelsproducten/2752093.html
• 17 Mathaes R, Koulov A, Joerg S, Mahler HC. Subcutaneous injection volume of biopharmaceuticals-pushing the boundaries. J Pharm Sci 2016; 105 (08) 2255-2259
• 18 Barg AA, Avishai E, Budnik I. et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Pediatr Blood Cancer 2019; 66 (11) e27886